Precipio Inc
NASDAQ:PRPO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Precipio Inc
Cash from Operating Activities
Precipio Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Precipio Inc
NASDAQ:PRPO
|
Cash from Operating Activities
$685k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cash from Operating Activities
$1.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
7%
|
|
|
CVS Health Corp
NYSE:CVS
|
Cash from Operating Activities
$10.6B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
2%
|
|
|
Cigna Corp
NYSE:CI
|
Cash from Operating Activities
$9.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
13%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cash from Operating Activities
$1.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
5%
|
|
|
Guardant Health Inc
NASDAQ:GH
|
Cash from Operating Activities
-$184.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
Precipio Inc
Glance View
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. The company is headquartered in Omaha, Nebraska and currently employs 55 full-time employees. The company went IPO on 2000-07-18. The firm is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells, T-cells and plasma cells. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture-based tests in a cytogenetics laboratory to imitate in-vivo conditions. HemeScreen technology was developed by the Company targeting Myeloproliferative Neoplasms (MPN), which has evolved into a suite of robust genetic diagnostic panels. ICP technology was developed at Harvard and is licensed exclusively by Dana-Farber. Its laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha.
See Also
What is Precipio Inc's Cash from Operating Activities?
Cash from Operating Activities
685k
USD
Based on the financial report for Dec 31, 2025, Precipio Inc's Cash from Operating Activities amounts to 685k USD.
What is Precipio Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 1Y
56%
Over the last year, the Cash from Operating Activities growth was 56%.
